医学
塞库金单抗
银屑病
内科学
伊克泽珠单抗
队列研究
不利影响
倾向得分匹配
队列
狼牙棒
相对风险
炎症性肠病
风险因素
回顾性队列研究
置信区间
恶性肿瘤
疾病
银屑病性关节炎
风险评估
门诊就诊
低风险
流行病学
门诊部
乌斯特基努马
产品特性概述
斑块性银屑病
作者
Maria C. Schneeweiss,Joseph Frank Merola,Yinzhu Jin,Richard Wyss,Priyanka Anand,Arash Mostaghimi,Sebastian Schneeweiß,Robert J. Glynn
标识
DOI:10.1177/24755303261446193
摘要
Background: Safety outcomes from IL-17A inhibitors have not been fully evaluated. Objective: Compare the risk of seven safety outcomes in patients with psoriasis who started treatment with either ixekizumab or secukinumab vs other biologics to treat psoriasis. Methods: In this cohort study (Apr 2016 - Dec 2022), we used US claims data to assess the risk of infections, major adverse cardiac events (MACE), inflammatory bowel disease (IBD), malignancy, and anaphylaxis, in patients with psoriasis starting an IL-17A inhibitor vs other biologics (TNF, IL-12/23, or IL-23 inhibitors). Results: Among 4261 IL-17A inhibitors users we observed no meaningfully increased risk of MACE (RR = 0.67, 0.27-1.63), or malignancy (RR = 0.92, 0.58-1.45) vs patients initiating other biologics. After propensity score matching IL-17A inhibitors users had a 3-fold increase in the risk of oral candidiasis (RR = 3.43; 1.48-7.84), a 19% increase in the risk of outpatient infections (RR = 1.19; 1.05-1.35) and a 40% increased risk of serious infections with wide confidence intervals (RR = 1.40; 0.72-2.71). We observed a signal for an increased risk of IBD based on very few events. Conclusion: Patients with psoriasis using an IL-17A inhibitor had an increased risk of oral candidiasis and outpatient infections but no increase for MACE, anaphylaxis, or malignancy compared to other biologics.
科研通智能强力驱动
Strongly Powered by AbleSci AI